Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosdevirine Dose-Finding Study in ART-Naive HIV-1
NCT01231555Phase 2Terminated
- Sponsor
- ViiV Healthcare
- Start
- Nov 2010
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, single-blind trial of Fosdevirine in human immunodeficiency virus type 1 infection (HIV-1) (3 arms), sponsored by ViiV Healthcare. Primary endpoint: Proportion of subjects with HIV-1 RNA < 50 copies/mL at 16 weeks. Started Nov 2010; status: terminated.
02
Drugs
Fosdevirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01231555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01231555.